The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.
Watch our interview with Mark Lebwohl, M.D., where we discuss the recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.
